Pertussis: Persistent pathogen, imperfect vaccines

Expert Review of Vaccines

Volumn 2, Issue 1, 2003, Pages 113-127

  Yeh, Sylvia H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acellular; Bordetella; Epidemiology; Pertussis; Safety; Vaccine

Indexed keywords

ACELLULAR VACCINE; AMOXICILLIN; AZITHROMYCIN; CHLORAMPHENICOL; CLARITHROMYCIN; DIPHTHERIA PERTUSSIS TETANUS VACCINE; ERYTHROMYCIN; ERYTHROMYCIN ESTOLATE; IMMUNOGLOBULIN; MACROLIDE; PERTUSSIS VACCINE;

ADOLESCENCE; ADULTHOOD; ANOREXIA; ANTIBIOTIC THERAPY; BORDETELLA PERTUSSIS; BRAIN DISEASE; BRAIN HEMORRHAGE; CAUSE OF DEATH; CHILDHOOD; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; DROWSINESS; DRUG SYNTHESIS; EDEMA; ERADICATION THERAPY; ERYTHEMA; FEVER; HUMAN; IMMUNOGENICITY; INGUINAL HERNIA; IRRITABILITY; NONHUMAN; PAIN; PATHOGENESIS; PERTUSSIS; PETECHIA; PNEUMONIA; PNEUMOTHORAX; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECTUM PROLAPSE; REVIEW; RISK ASSESSMENT; SEIZURE; SIDE EFFECT; SINUSITIS; UMBILICAL HERNIA; URINE INCONTINENCE; VOMITING; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; ANTIBODIES, BACTERIAL; BORDETELLA PERTUSSIS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE; HUMANS; INFANT; PERTUSSIS VACCINE; VACCINES, ACELLULAR; VACCINES, INACTIVATED; VIRULENCE; WHOOPING COUGH;

EID: 0038668793     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.2.1.113     Document Type: Review

References (118)

1. I Brennan M, Strebel P, George H et al. Evidence for transmission of pertussis in schools, Massachusetts, 1996: epidemiologic data supported by pulsed-field gel electrophoresis. J. Infect. Dis. 181, 210-215 (2000).
2. Gehanno JF, Pestel-Caron M, Nouvellon M, Caillard JF. Nosocomial pertussis in healthcare worders from a pediatric emergency unit in France. Infect. Control Hosp. Epidemiol. 20, 549-552 (1999).
3. Centers for Disease Control and Prevention. Pertussis outbreak-Vermont 1996. MMWR 46, 8226 (1997).
4. de Melker HE, Conyn-van Spaendonck MAE, Rumke HC, Wijngaarden JK van, Mooi FR, Schellekens JFP. Pertussis in the Netherlands: an outbreak despite high levels of immunization with whole cell vaccine. Emerg. Infect. Dis. 3, 175-178 (1997).
5. Van der Zee A, Groenendijk H, Peeters M et al. The differenciation of B. parapertussis and B. bronchiceptica from man and animals as determinded by DNA polymorphism mediated by two different insertion sequence elements suggests their phylogenetic relationship. Int. J. Syst. Bacteriol. 46, 640-647 (1996)
6. Huang CC, Chen PM, Kuo JK et al. Experimental whooping cough. N. Engl. J. Med 266, 105-111 (1962).
7. Ashworth LAE, Fitzgeorge RB, Irons LI, Morgan CP, Robinson A. Rabbit nasopharyngeal colonization by Bordetella pertussis: the effects of immunization on clearance and on serum and nasal antibody levels. J. Hyg. Camb. 88, 475-486 (1982).
8. Hornibrook JW, Ashburn LL. A study of experimental pertussis in the young rat. Pub. Health Rep. 54, 439-444 (1939).
9. Halperin SA, Heifetz SA, Kasina A. Experimental respiratory infection with Bordetella pertussis in mice: Comparison of two methods. Clin. Invest. Med 11, 297-303 (1988).
10. Parton R. Review of the biology of Bordetella pertussis. Biologicals 27, 71-76 (1999).
11. Goldman WE, Klapper DG, Baseman JB. Dectection, isolation and analysis of a released Bordetella pertussis product toxic to cultured tracheal cells. Infect. Immun. 36, 782-794 (1982).
12. Heininger U. Recent progress in clinical and basic pertussis research. Eur. J. Pediatr 160, 203-213 (2001). Contains survey of European vaccination schedules.
13. Weiss AA, Hewlett EL, Myers GA, Falkow S. Pertussis toxin and extracytoplasmic adnylate cyclase as virulence factors of Bordetella pertussis. Infect. Immun. 43, 263-269 (1984).
14. Mattoo S, Miller JF, Cotter PA. Role of Bordetella bronchiseptica fimbriae in tracheal colonization and development of a humoral immune response. Infect. Immun. 68, 2024-2033 (2000).
15. Cotter PA, Miller JF. Genetic anaylsis of Bordetella-host interaction. Ann. NY Acad. Sci. 797, 65-76 (1996).
16. Brennan MJ, Li ZM, Cowell JL et al. Identification of a 69-kilodalton nonfimbrial protein as an aglutinogen of Bordetella pertussis. Infect. Immun. 56, 3189-3195 (1988).
17. Hewlett EL. A commentary on the pathogenesis of pertussis. Clin. Infect Dis. 23 (Suppl. 2), S94-98 (1999).
18. Pittman M. The concept of pertussis as a toxin-mediated disease. Pediatr. Infect. Dis. J. 3, 467-486 (1984).
19. Wirsing von Konig CH, Finger H. Role of pertussis toxin in causing symptoms of Bordetella parapertussis infection. Eur. J. Clin. Microbiol. Infect. Dis. 13, 455-458 (1994).
20. Toyota T, Kai Y, Kakizaki M et al. Effects of islet-activating protein (IAP) on blood glucose and plasma insulin in healthy volunteers (phase 1 studies). Tohoku. Exp. Med 130, 105-16 (1980).
21. Mattoo S, Foreman-Wykert AK, Cotter PA, Miller JF. Mechanism of Bordetella pathogeneisis. Front. Biosci. 6, E168-186 (2001).
22. Cherry JD. The epidemiology of pertussis and pertussis immunization on in the United Kingdom and the United States: a comparative study. Curr. Probl. Pediatr. 14, 1-78 (1984).
23. Centers for Disease Control and Prevention: Pertussis - United States, January 1992-June 1995. MMWR 44, 525-529 (1995).
24. Centers for Diseases Control and Prevention, Pertusis - United States, 1997-2002, MMWR 51 (04), 76 (2002).
25. Bass JW, Stephenson SR. The return of pertussis. Pediatr. Infect. Dis. 6, 141-144 (1978).
26. Mertsola J, Ruuskanen O, Eerola E, Viljanen MK. Intrafamilial spread of pertussis. J. Pediatr. 103, 359-363 (1983).
27. Cromer BA, Goydos J, Hackell J, Mezzatesta J, Dekker C, Mortimer EA. Unrecognized pertussis infections in adolescents. Am. J. Dis. Child 147, 575-577 (1993).
28. Cattaneo LA, Reed GW, Haase DH, Wills MJ, Edwards KM. The seroepidemiology of Bordetella pertussis infection: A study of persons ages 1-65. J Infect Dis 173, 1256-1259 (1996).
29. Yih WK, Lett SM, de Vignes FN, Garrison KM, Sipe PL, Marchant CD. The increasing incidence of pertussis in Massachusetts adolescents and adults 1989-1998. J. Infect. Dis. 182, 1409-1416 (2000).
30. Wright SW, Decker MD, Edwards KM. Incidence of pertussis infection in healthcare workers. Infect. Control Hosp. Epidemiol 20, 120-123 (1999).
31. Mink CM, Cherry JD, Christ PD et al. A search for Bordetella pertussis infection in university students. Clin. Infect. Dis. 14, 464-471 (1992).
32. Schmitt-Grohe S, Cherry JD, Heininger U, Uberall MA, Pineda E, Stehr A. Pertussis in German adults. Clin. Infect. Dis. 21, 860- 866 (1995).
33. Wright SW, Edwards KK, Decker MD, Seldin ME. Pertussis infection in adults with persistent cough. JAMA 273, 1044-1046 (1995).
34. Ward JI, APERT Study Group: Pertussis epidemiology and acellular pertussis vaccine efficacy in older children: NIH APERT multi-center pertussis trial. Peadiatric Academic Society Meeting, Abst #752816 (2001).
35. Mortimer EA Jr. Pertussis and its prevention: a family affair. J. Infect. Dis. 161, 473-479 (1990). Review of epidemiology of pertussis transmission.
36. Valenti WM, Pincus PH, Messner MK. Nosocomial pertussis: possible spread by a hospital visitor. Am. J. Dis. Child. 134, 520-527 (1980).
37. Beiter A, Lewis K, Pineda EF, Cherry JD. Unrecognized maternal peripartum pertussis with subsequent fatal neonatal pertussis. J. Obstet. Gynecology 82, 691-693 (1993).
38. Lee LH, Pichichero ME. Costs of illness due to Bordetella pertussis in families. Arch. Fam. Med. 9, 989-996 (2000).
39. th Ed.). Feigin RD, Cherry JD (Eds.), WB Saunders Comp., Philadelphia, PA, USA (1998).
40. Mannerstedt G. Pertussis in adults. J. Pediatr 5, 596-600 (1934).
41. Maclean DW. Adults with pertussis. J. Royal College Gen. Practitioners 32, 298-300 (1982).
42. Aoyama T, Takeuchi Y, Goto A, Iwai H, Murase Y, Iwata T. Pertussis in adults. Am. J. Dis. Child. 146, 163-166 (1992).
43. Senzilet LD, Halperin SA, Spika JS et al. Pertussis is a frequent cause of prolonged cough illness in adults and adolescents. Clin. Infect. Dis. 32, 1691-1687 (2001).
44. Long SS, Welkon Ci, Clark JL Widespread silent transmission of pertussis in families: antibody correlates of infection and symptomatology. J. Infect. Dis. 161, 480-486 (1990).
45. Deen JL, Mink CM, Cherry JD et al. A household contact study of Bordetella pertussis infections. Clin. Infect. Dis. 21, 1211-1219 (1995).
46. Halperin SA, Wang EEL, Law B et al. Epidemiological features of pertussis in hospitalized patients in Canada, 1991-1997: Report of the Immunization Monitoring Program-Active (IMPACT). Clin. Infect. Dis. 28, 1238-1243 (1999).
47. De Serres G, Shadmani R, Duval B et al. Morbidity of pertussis in adolescents and adults, J. Infect. Dis. 182, 174-179 (2000).
48. Deek S, De Serres G, Boulianne N et al. Failure of physicians to consider the diagnosis of pertussis in children. Clin. Infect. Dis. 28, 840-846 (1999).
49. Muller FM, Hoppe JE, Wirsing von Konig CH. Laboratory diagnosis of pertussis: State of the art in 1997. J. Clin. Microbiol. 35, 2435-2443 (1997). Detailed review of laboratory diagnosis.
50. Murphy T, Bisgard K, Sanden G. Diagnosis and laboratory methods. In: Guidelines for the Control of Pertussis Outbreaks. Centers for Disease Control and Prevention, Atlanta, GA, USA (2000).
51. Jackson LA, Cherry JD, Wang SP, Grayston JT. Frequency of serologic evidence of Bordetella infections and mixed infections with other respiratory pathogens in university students with cough illnesses. Clin. Infect. Dis. 31, 3-6 (2000).
52. Lievano FA, Reynolds MA, Waring AL et al. Issues associated with and recommendations for using PCR to detect outbreaks of pertussis. J. Clin. Microbiol. 40, 2801-2805 (2002).
53. Hoppe JE. State of art in antibacterial susceptibility of Bordetella pertussis and antibiotic treatment of pertussis. Infection 26, 242-246 (1998).
54. Bass JW, Klenk EL, Kotheimer JB et al. Antimicrobial treatment of pertussis. J. Pediatr. 75, 768-781 (1996).
55. Booher CE, Farrell JB, West EJ. Pertussis: Clinical comparison of the newer antibiotics. J. Pediatr. 38, 411-422 (1951).
56. Report of the Medical Research Counsel. Treatment of whooping-cough with antibiotics. Lancet 1, 1109-1112 (1953).
57. Weinstein L, Seltser R, Marrow CT. The treatment of pertussis with aureomycin, chloramphenicol and terramycin. J. Pediatr. 39, 549-59 (1951).
58. Lewis K, Saubolle MA, Tenover FC, Rudinsky MF, Barbour SD, Cherry JD. Pertussis caused by an erythromycin-resistant strain of Bordetella pertussis. Pediatric Infect. Dis. J. 14, 388-391 (1995).
59. Korgenski EK, Daly JA. Surveillance and detection of erythromycin resistance in Bordetella pertussis isolates recovered from a pediatric population in the Intermountain West Region of the United States. J. Clin. Microbiol. 35, 2989-2991 (1997).
60. Wison KE, Cassiday PK, Popovic T, Sanden GN. Bordetella pertussis isolates with a heterogeneous phenotype for erythromycin resistance. J. Clin. Microbiol. 40, 2942-2944 (2002).
61. Bergquist S, Bernander S, Dansjo H, Sundelof B. Erythromycin in the treatment of pertussis: a study of bacteriologic and clinical effects. Pediatr. Infect. Dis. J. 6, 458-461 (1987).
62. Hoppe JE, Erythromycin Study Group. Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of pertussis. Pediatr. Infect. Dis. J. 11, 189-193 (1992).
63. Halperin SA, Bortolussi R, Langley JM, Miller B, Eastwood BJ. Seven days of erythromycin estolate is as effective as fourteen days for treatment of Bordetella pertussis infections. Pediatrics 100, 65-71 (1997).
64. Lebel MH, Mehra S. Efficacy and safety of darithromycin versus erythromycin for the treatment of pertussis: a prospective, randomized, single blind trial. Pediatr. Infect. Dis. J. 20, 1149-1154 (2001).
65. Amoyama T, Sunakawa K, Iwata S, Takeuchi Y, Fujii R. Efficacy of short-term treatment of pertussis with darithromycin and azithromycin. J. Pediatr. 129, 761-764 (1996).
66. Bace A, Zrnic T, Begovac J, Kuzmanovic N, Culig J. Short-term treatment of pertussis with azithromycin in infants and young children. Eur. J. Clin. Microbiol Infect. Dis. 18, 296-298 (1999).
67. Biellik RJ, Patriarca PA, Mullen JR et al. Risk factors for community- and household-acquired pertussis during a large-scale outbreak in Central Wisconsin. J. Infect. Dis. 157, 1134-1141 (1998).
68. Sprauer MA, Cochi SL, Zell ER et al. Prevention of secondary transmission of pertussis in households with early use of erythromycin. Am. J. Dis. Child 146, 177-181 (1992).
69. De Serres G, Boulianne N, Duval B. Field effectiveness of erythromycin prophylaxis to prevent pertussis within families. Pediatr. Infect. Dis. J. 14, 969-975 (1995).
70. Wirsing von Konig CH, Postels-Multani S, Bogaerts H et al. Factors influencing the spread of pertussis in households. Eur. J. Pediatr. 157, 391-394 (1998)
71. Halperin SA, Bortolussi R, Langley JM, Eastwood BJ, De Serres G. A randomized, placebo-controlled trial of erythromycin estolate chemoprophylaxis for household contacts of children with culture-positive Bordetella pertussis infection. Pediatrics 104, e42 (1999).
72. Honein MA, Paulozzi LJ, Himelright IM et al. Infantile hypertophic pyloric stenosis after pertussis prophylaxis with erythromycin: a case review and cohort study. Lancet 354, 2101-2105 (1999).
73. Bruss JB, Siber GR. Protective effects of pertussis immunoglobulin (P-IVIG) in the aerosol challenge model. Clin. Diag. Lab. Immun. 6, 464-470 (1999).
74. Bruss JB, Malley R, Halperin S et al. Treatment of severe pertussis: a study of the safety and pharmacology of iv. pertussis immunoglobulin. Pediatr. Infect. Dis. J. 18, 505-511 (1999).
75. Krantz I, Norrby SF, Trollfors B. Salbutamol versus placebo for treatment of pertussis. Pediatr. Infect. Dis. 4, 638-640 (1985).
76. Roberts I, Gavin R, Lennon D. Randomized controlled trial of steroids in pertussis. Pediatr. Infect. Dis. J. 11, 982-983 (1992).
77. rd Ed.). Plotkin SA, Orenstein WA (Eds). WB Saunders Comp., Philadelphia, PA, USA (1999). Comprehensive evaluation and critique of all pertussis vaccines.
78. Storsaeter J, Hallander HO, Gustafsson L, Olin P. Levels of antipertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 15, 1907-1916 (1998).
79. Cherry JD, Gornbein J, Heininger U, Stehr K. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 16, 1901-1906 (1998).
80. Ryan M, Murphy G, Gothefors L, Nilsson L, Storsaeter J, Mills KH. Bordetella pertussis respiratory infection in children is associated with preferential activation of Type 1 T-helper cells. J. Infect. Dis. 175, 1246-1250 (1997).
81. He Q, Tran Mink NH, Edelman K, Viljanen MK, Arvilommi H, Mertsola J. Cytokine mRNA expression and proliferative responses induced by pertussis toxin, filamentous hemagglutinin and pertactin of Bordetella pertussis in the peripheral blood mononuclear cells of infected and immunized schoolchildren and adults. Infect. Immun. 66, 3796-3801 (1998).
82. Ausiello CM, Urbani F, Sala A, Lande R, Cassone A. Vaocine- and antigen-dependent Type 1 and Type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines. Infect. Immun. 65, 2168-2174 (1997).
83. Zepp F, Knuf M, Habermehl P et al. Pertussis-specific cell-medicated immunity in infants after vaccination with tricomponent acellular pertussis vaccine. Infect Immun. 64, 4078-4084 (1996).
84. Salmaso S, Mastrantonio P, Wassilak SGF et al. Persistence of protection through 33 months of age provided by immunization in infantcy with two three-component acellular pertussis vaccines. Vaccine 13, 1270-1275 (1998).
85. Mahon BP, Brady MT, Mills KH. Protection against Bordetella pertussis in mice in the absence of detectable circulating antibody: Implications for long-term immunity in children. J. Infect. Dis. 181, 2087-2091 (2000).
86. Olin P, Storsaeter J. Vaccine efficacy. In: A Clinical Trial of Acellular Pertussis Vaccines in Sweden Technical Report. Stockholm, National Bacteriolgocial Laboratory, 1-28 (1988).
87. Madsen T. vaccination against wooping cough. JAMA 101, 187-188 (1933)
88. Schmitt H-J, Wirsing von Konig CH, Neiss A et al. Efficacy of a two-component acellular pertussis vaccine in early childhood after household exposure. JAMA 275, 37-41 (1996).
89. Liese JG, Meschievitz CK, Harzer E et al. Effiacy of a two-component acellular pertussis vaccine in infants. Pediatr. Infect. Dis. J. 16, 1038-1044 (1997)
90. Simondon F, Prezisosi MP, Yam A et al. A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine 15, 1606-1612 (1997).
91. Stehr K, Cherry JD, Heininger U et al. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP vaccine or DT vaccine). Pediatrics 101, 1-11 (1998).
92. Gustafsson L, Hallander HO, Olin P et al. A controlled trial of a two component acellular, a five-component acellular and a whole-cell pertussis vaccine. N. Engl. J. Med 334, 349-355 (1996).
93. Greco D, Salmaso S, Mastrantonio P et al. A controlled trial of two cellular vaccines and one whole-cell vaccine against pertussis. N. Engl. J. Med. 334, 341-348 (1996).
94. Onorato IM, Wassilak SG, Mead B. Efficacy of whole-cell pertussis vaccine in preschool children in the United States. JAMA 267, 2745-2749 (1992).
95. Cody CL, Baraff LJ, Cherry JD, Marcy SM, Manclark CR. Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children. Pediatrics 68, 650-660 (1981).
96. Blumberg DA, Lewis K, Mink CM, Christenson PD, Chatfield P, Cherry JD. Severe reactions associated with diphtheria-tetanus-pertussis vaccine: detailed study of children with seizures, hyptonic-hyporesponsive episodes, high fevers and persistent crying. Pediatrics 91, 1158-1165 (1993).
97. DuVernoy TS, Braun MM. Hypotonic-hyporesponsive episodes reported to the Vaccine Adverse Event Reporting System (VAERS), 1996-1998. Pediatrics 106, e52 (2000).
98. Miller DL, Wadsworth MJH, Ross EM. Pertussis vaccine and severe acute neurologic illnesses. Response to a recent review by members of the NCES team. Vaccine 7, 487-489 (1989).
99. Miller D, Madge N, Diamond J et al. Pertussis immunization and serious acute neurologic illnesses in children. Br. Med. J. 307, 1171-1176 (1993).
100. Howson CP, Fineberg HV. Adverse events following pertussis and rubella vaccines: Summary of a report of the Institute of Medicine JAMA 2667, 392-396 (1992)
101. Donnelly S, Loscher CE, Lynch MA, Mills KH. Whole-cell but not acellular pertussis vaccines induce convulsive activity in mice: Evidence of a role for toxin-induced interleukin1 beta in a new murine model for anaylsis of neuronal side effects of vaccination. Infect. Immun. 69, 4217-4223 (2001).
102. Trollfors B, Taranger J, Lagergard T et al. A placebo-controlled trial of pertussis-toxoid vaccine. N. Engl J. Med 333, 1045-1050 (1995).
103. Liese JG, Stojanov S, Foeschle J et al. Long-term efficacy of Biken acellular pertussis vaccine. Presented at NIAID Acellular Pertusssi Vaccine Conference, Bethesda, MD, USA, November 12-14, (2000).
104. Lugauer S, Heininger U, Cherry JD, Stehr K. Long-term clinical effectiveness of an acellular pertussis component vaccine and a whole-cell pertussis compoent vaccine. Eur. J. Pediatr. 161, 142-146 (2002).
105. Cherry JD. Comparative efficacy of acellular pertussis vaccines: An analysis of recent trials. Pediatr. Infect. Dis.J. 16 (Suppl. 4), S90-96 (1997).
106. Decker MD, Edwards KM, Steinhoff MC et al. Comparison of 13 acellular pertussis vaccines: Adverse reactions. Pediatrics 96, 557-566 (1995).
107. Rennels MB, Deloria MA, Pichichero ME et al. Extensive swelling after booster doses of acellular pertusis-tetanus-diphtheria vaccines. Pediatrics 105, e12 (2000)
108. Rosenthal S, Chen R, Hadler S. The safety of acellular pertussis vaccine vs. whole-cell pertussis vaccine. A postmarketing assessment. Arch. Pediatr. Adolesc. Med. 150, 457-460 (1996).
109. Centers for Disease Control and Prevention. Use of diphtheria toxoid-tetanus toxoid-acellular pertussis vaccine as a five-dose series: Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 49, 1-8 (2000).
110. Greenberg DP, Pickering LK, Senders SD et al. Interchangeability of 2 diphtheria-tetanus-acellular pertussis vaccines in infancy. Pedatrics 109, 666-72 (2002).
111. Bartels I, Jungert J, Lugauer S, Stehr K, Heininger U. Immunogenicity and reactogenicity of a single dose of a diphtheria-tetanus-acellular pertussis component vaccine (DTaP) compared to diphtheria-tetanus toxoid (Td) and a diphtheria toxoid (d) in adults. Vaccine 19, 3137-3145 (2001).
112. Schmirt HJ, Mohnike K, Zepp F, Herden P, Hosbach P. Immunogenicity and reactogenicity of the Biken acellular pertussis vaccine in young adults. Vaccine 19, 403-408 (2000).
113. Halperin SA, Smith B, Russell M et al. Adult formulation of a five component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine is safe and immunogenic in adolescents and adults. Pediatr Infect. Dis. J. 19, 276-283 (2000).
114. Edmunds WJ, Brisson M, Melegaro A, Gay NJ. The potential cost-effectiveness of acellular booster vaccination in England and Wales. Vaccine 20, 1316-1330 (2002)
115. Yeh SH, Ward JI, Cherry J, Miller JF, Cotter P, Relman D. Bordetella pertussis human challenge studies: Evaluation of pathogenesis and immunologic determinants of susceptibiiity, infection and protection. Presented at the NIAID Acellular Pertussis Vaccine Conference, Bethesda, MD, USA, November 12-14 (2000).
116. Weingart CL, Mobberley-Schuman PS, Hewlett EL, Gray MC, Weiss AA. Neutralizing antibodies to adenyl cyclase toxin promote phagocytosis of Bordetella pertussis by human neutrophils. Infect. Immun. 68, 7152-7155 (2000).
117. Watanabe M, Nagai M, Funaishi K, Endoh M. Efficacy of chemically cross-linked antigens for acellular pertussis vaccine. Vaccine 19, 1199-1203 (2000).
118. Roduit C, Bozzotti P, Mielcarek N et al. Immunogenicity and protective efficacy of neonatal vaccination against Bordetella pertussis in a murine model: evidence for early control of pertussis. Infect. Immun. 70, 3521-3528 (2002).